| Product Unit Size | Cost | Quantity | Stock |
|---|
LMK-235 is an HDAC inhibitor, selectively targeting HDAC4 and HDAC5. It induces apoptosis in multiple myeloma cells, a cancer type with a high rate of relapse. This activity is attributed to the downregulation of heme oxygenase-1 (HO-1), which is closely related to HDAC4, as well as increased phosphorylation of JNK.
| Cas No. | 1418033-25-6 |
|---|---|
| Purity | ≥98% |
| Formula | C15H22N2O4 |
| Formula Wt. | 294.35 |
| IUPAC Name | N-{[6-(Hydroxyamino)-6-oxohexyl]oxy}-3,5-dimethylbenzamide |
| Synonym | LMK235 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Marek L., Hamacher A., et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 56(2):427-36 (2013). PMID: 23252603.
Li X., Guo Y., et al. Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway. Life Sci. 223:146-157 (2019). PMID: 30876940.
